Hologic, Inc. (HOLX) Earns “Neutral” Rating from Bank of America Corporation
Hologic, Inc. (NASDAQ:HOLX)‘s stock had its “neutral” rating reaffirmed by analysts at Bank of America Corporation in a report released on Friday. They currently have a $48.00 price target on the medical equipment provider’s stock, up from their previous price target of $44.00. Bank of America Corporation’s target price points to a potential upside of 5.70% from the company’s previous close.
Several other analysts have also issued reports on HOLX. Stifel Nicolaus reissued a “buy” rating on shares of Hologic in a report on Friday, July 14th. Jefferies Group LLC set a $49.00 price objective on Hologic and gave the stock a “buy” rating in a research note on Sunday, May 28th. Barclays PLC reaffirmed an “overweight” rating and issued a $53.00 price objective (up previously from $50.00) on shares of Hologic in a research note on Monday. Piper Jaffray Companies reiterated a “buy” rating and issued a $51.00 target price on shares of Hologic in a research report on Friday, July 14th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $52.00 target price on shares of Hologic in a research report on Thursday, March 30th. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $47.79.
Hologic (NASDAQ:HOLX) opened at 45.41 on Friday. The company has a market cap of $12.72 billion, a P/E ratio of 16.28 and a beta of 0.91. The stock’s 50 day moving average price is $45.08 and its 200 day moving average price is $42.70. Hologic has a 1-year low of $35.15 and a 1-year high of $46.80.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.46 by $0.04. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The business had revenue of $715.40 million during the quarter, compared to analyst estimates of $685.24 million. During the same quarter in the previous year, the company posted $0.47 earnings per share. Hologic’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, equities analysts anticipate that Hologic will post $2.01 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Hologic, Inc. (HOLX) Earns “Neutral” Rating from Bank of America Corporation” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/21/hologic-inc-holx-earns-neutral-rating-from-bank-of-america-corporation.html.
In other news, Director Lawrence M. Levy sold 9,837 shares of the company’s stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $45.34, for a total transaction of $446,009.58. Following the transaction, the director now owns 40,577 shares of the company’s stock, valued at $1,839,761.18. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 101,108 shares of company stock worth $4,469,012. Insiders own 0.79% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in HOLX. Graybill Bartz & Assoc Ltd. boosted its position in shares of Hologic by 1.5% in the first quarter. Graybill Bartz & Assoc Ltd. now owns 59,185 shares of the medical equipment provider’s stock valued at $2,518,000 after buying an additional 885 shares during the period. Fox Run Management L.L.C. boosted its position in shares of Hologic by 117.2% in the first quarter. Fox Run Management L.L.C. now owns 12,600 shares of the medical equipment provider’s stock valued at $536,000 after buying an additional 6,800 shares during the period. Bank of Montreal Can boosted its position in shares of Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock valued at $136,448,000 after buying an additional 1,295,885 shares during the period. National Pension Service boosted its position in shares of Hologic by 55,168.1% in the first quarter. National Pension Service now owns 244,285 shares of the medical equipment provider’s stock valued at $10,433,000 after buying an additional 243,843 shares during the period. Finally, Gulf International Bank UK Ltd boosted its position in shares of Hologic by 1.5% in the first quarter. Gulf International Bank UK Ltd now owns 74,164 shares of the medical equipment provider’s stock valued at $3,155,000 after buying an additional 1,100 shares during the period. 94.04% of the stock is currently owned by institutional investors.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.